IP Library › Granted Patent US 12,569,501
Granted Patent B2
US 12,569,501 · App. 18/046,244 · Granted Mar 10, 2026

Neurosteroids and enantiomers thereof for the prevention and treatment of neurodegenerative conditions

Inventors: Douglas Covey (St. Louis, MO); Charles Zorumski (St. Louis, MO); Yukitoshi Izumi (St. Louis, MO); Makoto Ishikawa (St. Louis, MO)
Assignee: Washington University
A61K31/57A61K9/0019A61K9/0048A61K47/40A61P27/06
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,569,501
App. No.
18/046,244
Granted
Mar 10, 2026
Kind
B2
Abstract

The present disclosure is directed to a composition for prevention or treatment of neurodegenerative conditions. The composition comprises a neurosteroid, a synthetic enantiomer of a neurosteroid, or a combination thereof.

Claims (13)

1 . A composition comprising a synthetic enantiomer of a neurosteroid or a combination of the synthetic enantiomer of a neurosteroid and a neurosteroid;

wherein the composition is present in an amount effective to prevent or treat a neurodegenerative condition selected from the group consisting of glaucoma, age-related macular degeneration, retinal vascular occlusion, diabetic retinopathy, and Alzheimer's disease;

wherein the synthetic enantiomer of a neurosteroid or the combination of the synthetic enantiomer of a neurosteroid and a neurosteroid is present at a concentration of from about 10 nM to about 1 μM.

2 . The composition of claim 1 , further comprising a saline solution.

3 . The composition of claim 1 , further comprising (2-Hydroxypropyl)-β-cyclodextrin.

4 . The composition of claim 1 , wherein the neurosteroid is allopregnanolone and the synthetic enantiomer of the neurosteroid is ent-allopregnanolone.

5 . The composition of claim 1 , wherein the composition comprises both the neurosteroid and the synthetic enantiomer of the neurosteroid.

6 . The composition of claim 1 , wherein the neurosteroid is selected from the group consisting of cholesterol, pregnenolone, progesterone, pregn-5α-ane-3,17-dione, pregn-5β-ane-3,17-dione, androsterone, etiocholanolone, and tetrahydrodeoxycorticosterone.

7 . The composition of claim 1 , wherein the synthetic enantiomer of the neurosteroid is selected from the group consisting of ent-cholesterol, ent-pregnenolone, ent-progesterone, ent-pregn-5α-ane-3,17-dione, ent-pregn-5β-ane-3,17-dione, ent-androsterone, ent-etiocholanolone, and ent-tetrahydrodeoxycorticosterone.

8 . The composition of claim 1 , wherein the neurosteroid is progesterone and the synthetic enantiomer of the neurosteroid is ent-progesterone.

9 . A method of preventing or treating a neurodegenerative condition, the method comprising administering an effective amount of a composition comprising a synthetic enantiomer of a neurosteroid or a combination of the synthetic enantiomer of a neurosteroid and a neurosteroid;

wherein the neurodegenerative condition is selected from the group consisting of glaucoma, age-related macular degeneration, retinal vascular occlusion, diabetic retinopathy, and Alzheimer's disease;

wherein the synthetic enantiomer of a neurosteroid or the combination of the synthetic enantiomer of a neurosteroid and a neurosteroid is present at a concentration of from about 10 nM to about 1 μM.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 13, 2022
From: COVEY, DOUGLAS; ZORUMSKI, CHARLES; IZUMI, YUKITOSHI; ISHIKAWA, MAKOTO
To: WASHINGTON UNIVERSITY
Reel/Frame 061413/0089 →
Continuity (4)
Continuation 16782406 · Feb 5, 2020
Provisional Application 62801187 · Feb 5, 2019
Related Publication 20230058339A1 · Feb 23, 2023
Related Publication 20240041898A9 · Feb 8, 2024
References Cited (16)
US 10202413B2 · Covey · 2019 [cited by applicant]
US 11497754B2 · Covey · 2022 [cited by examiner]
US 20110306579A1 · Stein · 2011 [cited by applicant]
US 20130090317A1 · Vanlandingham et al. · 2013 [cited by applicant]
US 20150366953A1 · Danias et al. · 2015 [cited by applicant]
US 20160184322A1 · Vanlandingham et al. · 2016 [cited by applicant]
WO 2017156103A1 · 2017 [cited by applicant]
Mellon, Synthia H. et al. “Endogenous and synthetic neurosteroids in treatment of Niemann Pick Type C Disease.” Brain Res Rev. (Mar. 2008), vol. 57(2): 410-420. (Year: 2008). [cited by examiner]
“Reconstitution of Solutions.” Basicmedicalkey.com. (Feb. 11, 2017). Accessed Dec. 16, 2021. Available from: << https://basicmedicalkey.com/reconstitution-of-solutions/ >> . (Year: 2017). [cited by examiner]
Yokoo, M. et al. “2-Hydroxypropyl-β-cyclodextrin Acts as a Novel Anticancer Agent.” PLOS One. (Nov. 4, 2015), 10(11), pp. 1-20/20. (Year: 2015). [cited by examiner]
Goldman, David, “intracameral therapy: The next step in management of ocular disease?”, Ophthalmology Web, Sep. 19, 2008, Accessed Dec. 16, 2021, 2 pages. [cited by applicant]
Hirt et al., “Contribution of autophagy to ocular hypertension and neurodegeneration in the DBA/2J spontaneous glaucomo mouse model”, Cell Death Discovery, 2018, vol. 4, No. 75, 13 pages. [cited by applicant]
Ishikawa et al., “Neurosteroids Are Engogenous Neuroprotectants in an Ex Vivo Glaucoma Model”, IOVS, Dec. 2014, vol. 55, No. 12, pp. 8531-8541. [cited by applicant]
Ishikawa et al., “Additive neuroprotective effects of 24(S)-hydroxycholesterol and allopregnanolone in an ex vivo rate glaucoma model”, Scientific Reports, 2018, vol. 8, No. 12851, pp. 1-15. [cited by applicant]
“Reconstitution of Solutions”, Basicmedicalkey.com, Feb. 11, 2017, Accessed Dec. 16, 2021, Available from: <<https://basicmedicalkey.com/reconstitution-of-solutions/>>, 13 pages. [cited by applicant]
The Foundation/American Society of Retina Specialists, “Intravitreal Injections”, 2017, Accessed Dec. 16, 2021, 9 pages. [cited by applicant]